Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes mye
Myelodysplastic Syndromes (MDS)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa epoetin alfa: Epoetin alfa can help improv
Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option.
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
2024 EHA-ASCO Research Updates for MDS and AML
Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presenter(s)
Abhay Singh, MD, MPH
In this webinar, Dr. Abhay Singh discusses the latest MDS and AML research presented at the 2024 EHA and ASCO meetings. This is an advanced educational presentation.
Pashna N. Munshi, MD
Institution
University of Pennsylvania
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
High-Risk MDS - 2024 Philadelphia Patient and Family Conference
Topic(s)
Myelodysplastic Syndromes (MDS)
Keith W Pratz, MD, explains High-Risk MDS, or Myelodysplastic Syndromes, in this recorded conference session. He details risk categories as well as treatments, plus anticipated research on the disease.
A Patient Story - from the 2024 Philadelphia Patient and Family Conference
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Living Well with Bone Marrow Failure
Myelodysplastic Syndromes (MDS)
Ellen Kalinosky describes her turbulent journey through multiple bone marrow failure diseases in this recording from the 2024 Philadelphia Patient and Family Conference.
Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.